300 related articles for article (PubMed ID: 27644002)
1. Controversies over the use of GnRH agonists for reduction of chemotherapy-induced gonadotoxicity.
Garrido-Oyarzún MF; Castelo-Branco C
Climacteric; 2016 Dec; 19(6):522-525. PubMed ID: 27644002
[TBL] [Abstract][Full Text] [Related]
2. Preserving fertility when choosing chemotherapy regimens - the role of gonadotropin-releasing hormone agonists.
Blumenfeld Z; Evron A
Expert Opin Pharmacother; 2015 May; 16(7):1009-20. PubMed ID: 25826240
[TBL] [Abstract][Full Text] [Related]
3. Preservation of gonadal function in women undergoing chemotherapy: a review of the potential role for gonadotropin-releasing hormone agonists.
Hickman LC; Valentine LN; Falcone T
Am J Obstet Gynecol; 2016 Oct; 215(4):415-22. PubMed ID: 27422055
[TBL] [Abstract][Full Text] [Related]
4. 'An ounce of prevention is worth a pound of cure': the case for and against GnRH-agonist for fertility preservation.
Blumenfeld Z; Katz G; Evron A
Ann Oncol; 2014 Sep; 25(9):1719-1728. PubMed ID: 24651411
[TBL] [Abstract][Full Text] [Related]
5. Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in breast cancer patients.
Conte B; Del Mastro L
Minerva Ginecol; 2017 Aug; 69(4):350-356. PubMed ID: 28398024
[TBL] [Abstract][Full Text] [Related]
6. Endocrine prevention of chemotherapy-induced ovarian failure.
Blumenfeld Z; Evron A
Curr Opin Obstet Gynecol; 2016 Aug; 28(4):223-9. PubMed ID: 27253235
[TBL] [Abstract][Full Text] [Related]
7. Protecting Ovaries During Chemotherapy Through Gonad Suppression: A Systematic Review and Meta-analysis.
Elgindy E; Sibai H; Abdelghani A; Mostafa M
Obstet Gynecol; 2015 Jul; 126(1):187-95. PubMed ID: 26241272
[TBL] [Abstract][Full Text] [Related]
8. Endocrine prevention of chemotherapy-induced ovarian failure.
Blumenfeld Z
Future Oncol; 2016 Jul; 12(14):1671-4. PubMed ID: 27250801
[No Abstract] [Full Text] [Related]
9. Ovarian protection with gonadotropin-releasing hormone agonists during chemotherapy in cancer patients: From biological evidence to clinical application.
Lambertini M; Horicks F; Del Mastro L; Partridge AH; Demeestere I
Cancer Treat Rev; 2019 Jan; 72():65-77. PubMed ID: 30530271
[TBL] [Abstract][Full Text] [Related]
10. Preservation of fertility and ovarian function and minimalization of chemotherapy associated gonadotoxicity and premature ovarian failure: the role of inhibin-A and -B as markers.
Blumenfeld Z
Mol Cell Endocrinol; 2002 Feb; 187(1-2):93-105. PubMed ID: 11988316
[TBL] [Abstract][Full Text] [Related]
11. Medical approaches to preservation of fertility in female cancer patients.
Del Mastro L; Giraudi S; Levaggi A; Pronzato P
Expert Opin Pharmacother; 2011 Feb; 12(3):387-96. PubMed ID: 21254946
[TBL] [Abstract][Full Text] [Related]
12. How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries.
Blumenfeld Z
Oncologist; 2007 Sep; 12(9):1044-54. PubMed ID: 17914074
[TBL] [Abstract][Full Text] [Related]
13. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy.
Blumenfeld Z; Shapiro D; Shteinberg M; Avivi I; Nahir M
Lupus; 2000; 9(6):401-5. PubMed ID: 10981642
[TBL] [Abstract][Full Text] [Related]
14. Ovarian rescue/protection from chemotherapeutic agents.
Blumenfeld Z
J Soc Gynecol Investig; 2001; 8(1 Suppl Proceedings):S60-4. PubMed ID: 11223377
[TBL] [Abstract][Full Text] [Related]
15. GnRH-analogues for ovarian protection in childhood cancer patients: how adult hypotheses are relevant in prepubertal females.
Osborne SE; Detti L
Curr Drug Targets; 2013 Jul; 14(8):856-63. PubMed ID: 23614679
[TBL] [Abstract][Full Text] [Related]
16. Gonadotropin-releasing hormone agonist may minimize premature ovarian failure in young women undergoing autologous stem cell transplantation.
Blumenfeld Z; Patel B; Leiba R; Zuckerman T
Fertil Steril; 2012 Nov; 98(5):1266-70.e1. PubMed ID: 22935556
[TBL] [Abstract][Full Text] [Related]
17. Fertility after treatment for Hodgkin's disease.
Blumenfeld Z; Dann E; Avivi I; Epelbaum R; Rowe JM
Ann Oncol; 2002; 13 Suppl 1():138-47. PubMed ID: 12078896
[TBL] [Abstract][Full Text] [Related]
18. Ovarian function preservation with GnRH agonist in young breast cancer patients: does it impede the effect of adjuvant chemotherapy?
Kim J; Kim M; Lee JH; Lee H; Lee SK; Bae SY; Jun SY; Kil WH; Lee JE; Kim SW; Nam SJ
Breast; 2014 Oct; 23(5):670-5. PubMed ID: 25088482
[TBL] [Abstract][Full Text] [Related]
19. Strategies for fertility preservation in young early breast cancer patients.
Tomasi-Cont N; Lambertini M; Hulsbosch S; Peccatori AF; Amant F
Breast; 2014 Oct; 23(5):503-10. PubMed ID: 24934638
[TBL] [Abstract][Full Text] [Related]
20. Gonadotropin-releasing hormone agonists for ovarian protection during cancer chemotherapy: systematic review and meta-analysis.
Senra JC; Roque M; Talim MCT; Reis FM; Tavares RLC
Ultrasound Obstet Gynecol; 2018 Jan; 51(1):77-86. PubMed ID: 29055060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]